Vitamin D and kidney stone disease

Current Opinion in Nephrology and Hypertension

Volumn 22, Issue 4, 2013, Pages 383-389

  Tang, Jie ^a,b   Chonchol, Michel B ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

Author keywords

Calcium; Kidney stone disease; Vitamin D

Indexed keywords

CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; VITAMIN D;

BONE MINERAL; CALCIUM ABSORPTION; CALCIUM HOMEOSTASIS; CALCIUM URINE LEVEL; DISEASE ASSOCIATION; DRUG SAFETY; GENETIC ANALYSIS; GENETIC PREDISPOSITION; HUMAN; KIDNEY TUBULE ABSORPTION; NEPHROLITHIASIS; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; URINARY EXCRETION; VITAMIN D DEFICIENCY;

ANIMALS; CALCIUM; DIETARY SUPPLEMENTS; HOMEOSTASIS; HUMANS; KIDNEY; KIDNEY CALCULI; PREVALENCE; RISK FACTORS; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84879213209     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328360bbcd     Document Type: Review

References (68)

1. Elkoushy MA, Sabbagh R, Unikowsky B, Andonian S. Prevalence and metabolic abnormalities of vitamin D-inadequate patients presenting with urolithiasis to a tertiary stone clinic. Urology 2012; 79:781-785.
2. Eisner BH, Thavaseelan S, Sheth S, et al. Relationship between serum vitamin D and 24-h urine calcium in patients with nephrolithiasis. Urology 2012; 80:1007-1010.
3. Tang J, McFann KK, Chonchol MB. Association between serum 25-hydroxyvitamin D and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Nephrol Dial Transplant 2012; 27:4385-4389.
4. Shakhssalim N, Gilani KR, Parvin M, et al. An assessment of parathyroid hormone, calcitonin, 1,25 (OH)2 vitamin D3, estradiol and testosterone in men with active calcium stone disease and evaluation of its biochemical risk factors. Urol Res 2013; 39:1-7.
5. Sakhaee K, Maalouf NM, Kumar R, et al. Nephrolithiasis-associated bone disease: pathogenesis and treatment options. Kidney Int 2011; 79:393-403.
6. Melton LJ 3rd, Crowson CS, Khosla S, et al. Fracture risk among patients with urolithiasis: a population-based cohort study. Kidney Int 1998; 53:459-464.
7. Lauderdale DS, Thisted RA, Wen M, Favus MJ. Bone mineral density and fracture among prevalent kidney stone cases in the Third National Health and Nutrition Examination Survey. J Bone Miner Res 2001; 16:1893-1898.
8. Heilberg IP, Martini LA, Szejnfeld VL, et al. Bone disease in calcium stone forming patients. Clin Nephrol 1994; 42:175-182.
9. Suda T, Ueno Y, Fujii K, Shinki T. Vitamin D and bone. J Cell Biochem 2003; 88:259-266.
10. DeLuca HF. The vitamin D story: a collaborative effort of basic science and clinical medicine. FASEB J 1988; 2:224-236.
11. Shevde NK, Plum LA, Clagett-Dame M, et al. A potent analog of 1alpha, 25-dihydroxyvitamin D3 selectively induces bone formation. Proc Natl Acad Sci U S A 2002; 99:13487-13491.
12. Gardiner EM, Baldock PA, Thomas GP, et al. Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage. FASEB J 2000; 14:1908-1916.
13. Stechman MJ, Loh NY, Thakker RV. Genetics of hypercalciuric nephrolithiasis: renal stone disease. Ann N Y Acad Sci 2007; 1116:461-484.
14. Goldfarb DS, Fischer ME, Keich Y, Goldberg J. A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry. Kidney Int 2005; 67:1053-1061.
15. Resnick M, Pridgen DB, Goodman HO. Genetic predisposition to formation of calcium oxalate renal calculi. N Engl J Med 1968; 278:1313-1318.
16. Scott P, Ouimet D, Proulx Y, et al. The 1 alpha-hydroxylase locus is not linked to calcium stone formation or calciuric phenotypes in French-Canadian families. J Am Soc Nephrol 1998; 9:425-432.
17. Scott P, Ouimet D, Valiquette L, et al. Suggestive evidence for a susceptibility gene near the vitamin D receptor locus in idiopathic calcium stone formation. J Am Soc Nephrol 1999; 10:1007-1013.
18. Petrucci M, Scott P, Ouimet D, et al. Evaluation of the calcium-sensing receptor gene in idiopathic hypercalciuria and calcium nephrolithiasis. Kidney Int 2000; 58:38-42.
19. Cailhier JF, Petrucci M, Valiquette L, et al. Exclusion mapping of major crystallization inhibitors in idiopathic calcium urolithiasis. J Urol 2001; 166:1484-1486.
20. Khullar M, Relan V, Singh SK. VDR gene and urinary calcium excretion in nephrolithiasis. Kidney Int 2006; 69:943.
21. Mossetti G, Rendina D, Viceconti R, et al. The relationship of 3' vitamin D receptor haplotypes to urinary supersaturation of calcium oxalate salts and to age at onset and familial prevalence of nephrolithiasis. Nephrol Dial Transplant 2004; 19:2259-2265.
22. Seyhan S, Yavascaoglu I, Kilicarslan H, et al. Association of vitamin D receptor gene Taq I polymorphism with recurrent urolithiasis in children. Int J Urol 2007; 14:1060-1062.
23. Nishijima S, Sugaya K, Naito A, et al. Association of vitamin D receptor gene polymorphism with urolithiasis. J Urol 2002; 167:2188-2191.
24. Ozkaya O, Soylemezoglu O, Misirlioglu M, et al. Polymorphisms in the vitamin D receptor gene and the risk of calcium nephrolithiasis in children. Eur Urol 2003; 44:150-154.
25. Ferreira LG, Pereira AC, Heilberg IP. Vitamin D receptor and calcium-sensing receptor gene polymorphisms in hypercalciuric stone-forming patients. Nephron Clin Pract 2011; 114:c135-c144.
26. Zerwekh JE, Hughes MR, Reed BY, et al. Evidence for normal vitamin D receptor messenger ribonucleic acid and genotype in absorptive hypercalciuria. J Clin Endocrinol Metab 1995; 80:2960-2965.
27. Gunes S, Bilen CY, Kara N, et al. Vitamin D receptor gene polymorphisms in patients with urolithiasis. Urol Res 2006; 34:47-52.
28. Thorleifsson G, Holm H, Edvardsson V, et al. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet 2009; 41:926-930.
29. Meyer MB, Watanuki M, Kim S, et al. The human transient receptor potential vanilloid type 6 distal promoter contains multiple vitamin D receptor binding sites that mediate activation by 1,25-dihydroxyvitamin D3 in intestinal cells. Mol Endocrinol 2006; 20:1447-1461.
30. Dupret JM, Brun P, Perret C, et al. Transcriptional and posttranscriptional regulation of vitamin D-dependent calcium-binding protein gene expression in the rat duodenum by 1,25-dihydroxycholecalciferol. J Biol Chem 1987; 262:16553-16557.
31. Caniggia A, Gennari C, Cesari L. Intestinal absorption of 45Ca in stone-forming patients. Br Med J 1965; 1:427-429.
32. Pak CY, McGuire J, Peterson R, et al. Familial absorptive hypercalciuria in a large kindred. J Urol 1981; 126:717-719.
33. Levy FL, Adams-Huet B, Pak CY. Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. Am J Med 1995; 98:50-59.
34. Pak CY, Oata M, Lawrence EC, Snyder W. The hypercalciurias. Causes, parathyroid functions, and diagnostic criteria. J Clin Invest 1974; 54:387-400.
35. Kaplan RA, Haussler MR, Deftos LJ, et al. The role of 1 alpha, 25-dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria. J Clin Invest 1977; 59:756-760.
36. Yao J, Kathpalia P, Bushinsky DA, Favus MJ. Hyperresponsiveness of vitamin D receptor gene expression to 1,25-dihydroxyvitamin D3. A new characteristic of genetic hypercalciuric stone-forming rats. J Clin Invest 1998; 101:2223-2232.
37. Li XQ, Tembe V, Horwitz GM, et al. Increased intestinal vitamin D receptor in genetic hypercalciuric rats. A cause of intestinal calcium hyperabsorption. J Clin Invest 1993; 91:661-667.
38. Bushinsky DA, Favus MJ. Mechanism of hypercalciuria in genetic hypercalciuric rats. Inherited defect in intestinal calcium transport. J Clin Invest 1988; 82:1585-1591.
39. Favus MJ, Karnauskas AJ, Parks JH, Coe FL. Peripheral blood monocyte vitamin D receptor levels are elevated in patients with idiopathic hypercalciuria. J Clin Endocrinol Metab 2004; 89:4937-4943.
40. Bises G, Kallay E, Weiland T, et al. 25-hydroxyvitamin D3-1alpha-hydroxylase expression in normal and malignant human colon. J Histochem Cytochem 2004; 52:985-989.
41. Wang WH, Lu M, Hebert SC. Cytochrome P-450 metabolites mediate extracellular Ca(2+)-induced inhibition of apical K+ channels in the TAL. Am J Physiol 1996; 271:C103-C111.
42. Motoyama HI, Friedman PA. Calcium-sensing receptor regulation of PTH-dependent calcium absorption by mouse cortical ascending limbs. Am J Physiol Renal Physiol 2002; 283:F399-F406.
43. Blankenship KA, Williams JJ, Lawrence MS, et al. The calcium-sensing receptor regulates calcium absorption in MDCK cells by inhibition of PMCA. Am J Physiol Renal Physiol 2001; 280:F815-F822.
44. Yao JJ, Bai S, Karnauskas AJ, et al. Regulation of renal calcium receptor gene expression by 1,25-dihydroxyvitamin D3 in genetic hypercalciuric stone-forming rats. J Am Soc Nephrol 2005; 16:1300-1308.
45. Canaff L, Hendy GN. Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem 2002; 277:30337-30350.
46. Maiti A, Beckman MJ. Extracellular calcium is a direct effecter of VDR levels in proximal tubule epithelial cells that counter-balances effects of PTH on renal Vitamin D metabolism. J Steroid Biochem Mol Biol 2007; 103:504-508.
47. Coe FL, Favus MJ, Crockett T, et al. Effects of low-calcium diet on urine calcium excretion, parathyroid function and serum 1,25(OH)2D3 levels in patients with idiopathic hypercalciuria and in normal subjects. Am J Med 1982; 72:25-32.
48. Worcester EM, Coe FL. New insights into the pathogenesis of idiopathic hypercalciuria. Semin Nephrol 2008; 28:120-132.
49. Shen FH, Baylink DJ, Nielsen RL, et al. Increased serum 1,25-dihydroxyvitamin D in idiopathic hypercalciuria. J Lab Clin Med 1977; 90:955-962.
50. Broadus AE, Insogna KL, Lang R, et al. Evidence for disordered control of 1,25-dihydroxyvitamin D production in absorptive hypercalciuria. N Engl J Med 1984; 311:73-80.
51. Giannini S, Nobile M, Castrignano R, et al. Possible link between vitamin D and hyperoxaluria inpatients with renal stone disease. Clin Sci (Lond) 1993; 84:51-54.
52. Jarrar K, Amasheh RA, Graef V, Weidner W. Relationship between 1,25-dihydroxyvitamin-D, calcium and uric acid in urinary stone formers. Urol Int 1996; 56:16-20.
53. Leaf DE, Korets R, Taylor EN, et al. Effect of vitamin D repletion onurinary calcium excretion among kidney stone formers. Clin J Am Soc Nephrol 2012; 7:829-834.
54. Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008; 29:726-776.
55. Ihara H, Denhardt DT, Furuya K, et al. Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin. J Biol Chem 2001; 276:13065-13071.
56. Price PA, Baukol SA. 1,25-Dihydroxyvitamin D3 increases synthesis of the vitamin K-dependent bone protein by osteosarcoma cells. J Biol Chem 1980; 255:11660-11663.
57. Holtrop ME, Cox KA, Clark MB, et al. 1,25-dihydroxycholecalciferol stimulates osteoclasts in rat bones in the absence of parathyroid hormone. Endocrinology 1981; 108:2293-2301.
58. Krieger NS, Stathopoulos VM, Bushinsky DA. Increased sensitivity to 1,25(OH)2D3 in bone from genetic hypercalciuric rats. Am J Physiol 1996; 271:C130-C135.
59. Kim M, Sessler NE, Tembe V, et al. Response of genetic hypercalciuric rats to a low calcium diet. Kidney Int 1993; 43:189-196.
60. Fuss M, Pepersack T, Van Geel J, et al. Involvement of low-calcium diet in the reduced bone mineral content of idiopathic renal stone formers. Calcif Tissue Int 1990; 46:9-13.
61. Barkin J, Wilson DR, Manuel MA, et al. Bone mineral content in idiopathic calcium nephrolithiasis. Miner Electrolyte Metab 1985; 11:19-24.
62. Heller HJ, Zerwekh JE, Gottschalk FA, Pak CY. Reduced bone formation and relatively increased bone resorption in absorptive hypercalciuria. Kidney Int 2007; 71:808-815.
63. Raisz LG, Kream BE, Smith MD, Simmons HA. Comparison of the effects of vitamin D metabolites on collagen synthesis and resportion of fetal rat bone in organ culture. Calcif Tissue Int 1980; 32:135-138.
64. van der Eerden BC, Fratzl-Zelman N, Nijenhuis T, et al. The vitamin D analog ZK191784 normalizes decreased bone matrix mineralization in mice lacking the calcium channel TRPV5. J Cell Physiol 2012; 228:402-407.
65. Netelenbos JC, Jongen MJ, van der Vijgh WJ, et al. Vitamin D status in urinary calcium stone formation. Arch Intern Med 1985; 145:681-684.
66. Berlin T, Bjorkhem I, Collste L, et al. Relation between hypercalciuria and vitamin D3-status in patients with urolithiasis. Scand J Urol Nephrol 1982; 16:269-273.
67. Wallace RB, Wactawski-Wende J, O'Sullivan MJ, et al. Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements. Am J Clin Nutr 2012; 94:270-277.
68. Lips P. Interaction between vitamin D and calcium. Scand J Clin Lab Invest Suppl 2012; 243:60-64.